FindTrial
Sign In

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesilate in Patients With Inoperable or Recurrent Breast Cancer

Post-marketing surveillance of eribulin mesilate (Investigation of the clinical safety and effectiveness in patients with inoperable or recurrent breast cancer)

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222004
Enrollment
500
Registered
2013-01-22
Start date
2013-01-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

investigational material(s) Generic name etc : Eribulin Mesilate(Halaven) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Inves

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inoperable breast cancer Recurrent breast cancer

Exclusion criteria

Exclusion criteria: Corresponding to contraindication of eribulin mesilate Not applicable to indications of eribulin mesilate Not applicable to aggravation or recurrence of breast cancer in patients who have previously been treated with anthracycline and/or taxane antitumor drugs

Design outcomes

Primary

MeasureTime frame
Effectiveness diagnosed by imaging Effectiveness diagnosed through various imagings such as CT, MRI, Echo or X-ray—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026